These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24624536)

  • 1. A comparison of FDA and EMA drug approval: implications for drug development and cost of care.
    Howie LJ; Hirsch BR; Abernethy AP
    Oncology (Williston Park); 2013 Dec; 27(12):1195, 1198-1200, 1202 passim. PubMed ID: 24624536
    [No Abstract]   [Full Text] [Related]  

  • 2. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When EMA and FDA decisions conflict: differences in patients or in regulation?
    Wolfe SM
    BMJ; 2013 Aug; 347():f5140. PubMed ID: 23970394
    [No Abstract]   [Full Text] [Related]  

  • 4. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice.
    Trotta F; Leufkens HG; Schellens JH; Laing R; Tafuri G
    J Clin Oncol; 2011 Jun; 29(16):2266-72. PubMed ID: 21537038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian, European and United States new drug approval times now relatively similar.
    Rawson NSB
    Regul Toxicol Pharmacol; 2018 Jul; 96():121-126. PubMed ID: 29730446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD; White RS
    Issue Brief Health Policy Track Serv; 2014 Dec; ():1-96. PubMed ID: 25775703
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory review of novel therapeutics--comparison of three regulatory agencies.
    Downing NS; Aminawung JA; Shah ND; Braunstein JB; Krumholz HM; Ross JS
    N Engl J Med; 2012 Jun; 366(24):2284-93. PubMed ID: 22591257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

  • 13. The calculus of cures.
    Kocher R; Roberts B
    N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
    [No Abstract]   [Full Text] [Related]  

  • 14. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept.
    Mogielnicki M; Swieczkowski D; Bachorski W; Zuk G; Gilis-Malinowska N; Zarzeka A; Merks P; Gruchala M; Jaguszewski M
    Cardiol J; 2016; 23(5):515-517. PubMed ID: 27723064
    [No Abstract]   [Full Text] [Related]  

  • 15. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
    DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
    Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'New' FDA delivers in 2003.
    Schmidt E; Wong R
    Nat Rev Drug Discov; 2003 Dec; 2(12):941-2. PubMed ID: 14756139
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 19. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 20. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.